ADAP: Adaptimmune - Transforming T-Cell therapy

Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer 17.12.2015 | Nachricht | finanzen.net

PHILADELPHIA and OXFORD, United Kingdom, Dec. 17, 2015  -- Adaptimmune Therapeutics plc , a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has... | December 17,  2015

European biotechnology companies have been attracting increasing amounts of U.S. venture capital, regaining momentum that was shaken after the global recession.

This is the official website of the Loncar Cancer Immunotherapy Index (LCINDX)

PHILADELPHIA and OXFORD, United Kingdom, Jan.  07, 2016   -- Adaptimmune Therapeutics plc , a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it is... | January  7,  2016

Adaptimmune Therapeutics (ADAP) fell nearly 11% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up over 4% in the past one month.

Adaptimmune Announces New Additions to Manufacturing Senior Management 22.01.2016 | Nachricht | finanzen.net

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration 02.02.2016 | Nachricht | finanzen.net

GlaxoSmithKline has expanded its alliance with Adaptimmune to accelerate development of a groundbreaking cancer drug in a $500m deal that highlights the UK group’s efforts to rebuild its position in the oncology market. The FTSE 100 drugmaker said

George Robinson is unlikely to win many public accolades for his role as an early pioneer of the European hedge fund industry but what if he bankrolled a cure for cancer? The 59-year-old co-founder of Sloane Robinson, one of London’s longest-establis

THE first large clinical trial of a new kind of cancer treatment using a patient’s own natural “killer cells” to destroy solid tumours will begin within a year.